Mirati Therapeutics Presents Positive Preliminary Data From On-Going Clinical Trials Of Sitravatinib In Non-Small Cell Lung Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to Mirati Therapeutics Presents Positive Preliminary Data From On-Going Clinical Trials Of Sitravatinib In Non-Small Cell Lung Cancer

Mirati Therapeutics (MRTX) Trades at High, Up 150%

September 15, 2017 10:54 AM EDT

Mirati Therapeutics (NASDAQ: MRTX) Trades at High, Up 150%

... More

Mirati Therapeutics (MRTX) PT Raised to $9 at Leerink Partners

September 15, 2017 8:04 AM EDT

Leerink Partners raised its price target on Mirati Therapeutics (NASDAQ: MRTX) to $9.00 (from $7.00) while maintaining a Market Perform rating ahead of the IASLC 2017 Chicago Multidisciplinary Symposium in Thoracic Oncology. MRTX reported an encouraging update from its ongoing early stage clinical trials of anti-cancer... More